Verrica Pharmaceuticals Enters Material Definitive Agreement
Ticker: VRCA · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Aug 5, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
Related Tickers: VRCA
TL;DR
Verrica Pharma just signed a big deal, details TBD.
AI Summary
On August 2, 2024, Verrica Pharmaceuticals Inc. entered into a Material Definitive Agreement. The filing does not disclose the specific details or parties involved in this agreement, only that it is a significant event requiring immediate reporting.
Why It Matters
This filing indicates a significant new contract or partnership for Verrica Pharmaceuticals, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details about the agreement introduces uncertainty, making it difficult to assess the immediate impact or risks.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- August 2, 2024 (date) — Date of earliest event reported
FAQ
What type of Material Definitive Agreement did Verrica Pharmaceuticals Inc. enter into?
The filing does not specify the nature of the Material Definitive Agreement.
Who are the other parties involved in this Material Definitive Agreement?
The filing does not disclose the names of the other parties to the agreement.
What is the effective date of this Material Definitive Agreement?
The earliest event reported is August 2, 2024, which is also the date of the report.
Are there any financial terms or obligations associated with this agreement mentioned in the filing?
No financial terms or obligations related to the agreement are disclosed in this filing.
Does this agreement represent a new partnership, acquisition, or other significant business transaction?
The filing states it is a 'Material Definitive Agreement' but does not specify the exact nature of the transaction.
Filing Stats: 651 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-08-05 16:15:59
Filing Documents
- d856804d8k.htm (8-K) — 22KB
- 0001193125-24-193923.txt ( ) — 141KB
- vrca-20240802.xsd (EX-101.SCH) — 3KB
- vrca-20240802_lab.xml (EX-101.LAB) — 18KB
- vrca-20240802_pre.xml (EX-101.PRE) — 11KB
- d856804d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Verrica Pharmaceuticals Inc. Date: August 5, 2024 /s/ P. Terence Kohler, Jr. P. Terence Kohler, Jr. Chief Financial Officer